Beta Drugs Ltd (BETA) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Beta Drugs Ltd on NSE and BSE, with an AI summary of each filing.
Beta Drugs Limited has informed the Exchange about Transcript
Transcript · 28 Oct 2026, 10:27 pm
Beta Drugs Reports Strong H1 FY27 Performance with 45% PAT Growth Beta Drugs posted 29.2% YoY revenue growth for H1 FY27, with PAT rising ~45% YoY to INR34 crores and EBITDA margins at 23.18%. Management noted zero material impact from NPPA trade margin capping. Nivian Lifesciences grew 75% YoY to INR31 crores, while the API segment expanded 29% YoY, supported by an upcoming intermediate plant operational by Jan'27. Management reaffirmed medium-term revenue growth guidance of 20%–25% with 23%–24% sustained EBITDA margins, targeting INR150 crores in own-brand sales and INR90–100 crores in exports for FY27.
Beta Drugs Limited has informed the Exchange about Link of Recording
Others · 22 Oct 2026, 11:30 pm
Beta Drugs Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32
Others (Uncategorized) · 22 Oct 2026, 11:07 pm
Beta Drugs Reports Zero Deviation in Preferential Issue Proceeds Utilization Beta Drugs Limited confirmed nil deviation in utilizing funds from its ₹117.01 crore preferential issue (raised on 25th Nov'24) for the quarter ended 30th Sep'26. Against the allocated ₹117 crore, cumulative fund deployment reached ₹47.37 crore. Major deployments include ₹19.94 crore for capital investment/acquisitions (allocated ₹20 crore), ₹13.36 crore for general corporate purposes (allocated ₹15 crore), ₹9.52 crore for manufacturing capex (allocated ₹44 crore), and ₹3.60 crore for subsidiary facility upgrades. Brickwork Ratings India serves as the monitoring agency.
Beta Drugs Limited has informed the Exchange about Presentation
Intimation · 22 Oct 2026, 5:41 pm
Beta Drugs Reports Strong H1 FY27 Performance with 29% Topline Growth Beta Drugs posted strong H1 FY27 results, with revenue rising 29.2% YoY to INR 263 Cr and PAT increasing to INR 34 Cr (13.1% margin). EBITDA grew to INR 61 Cr with margins improving slightly to 23.2%, while gross margin expanded to 56.2% and ROCE reached 23.3%. Segment-wise, CMO led with INR 95 Cr (+21% YoY), Branded Products generated INR 71 Cr (+17% YoY), Exports rose to INR 43 Cr with 35 approvals, and Nivian surged 75% YoY to INR 31 Cr. Total borrowings declined significantly to INR 49 Cr.
Beta Drugs Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Financial Result · 22 Oct 2026, 4:43 pm
Beta Drugs Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR) ■ Revenue: 1,37,48,87,594 (+33.0% YoY | +9.5% QoQ) ■ EBITDA: 30,28,04,262 (+42.1% YoY | +10.6% QoQ) ■ EBITDA Margin (%): 22.0 (+141 bps YoY | +23 bps QoQ) ■ PAT: 18,55,07,075 (+51.8% YoY | +17.4% QoQ) ■ EPS (INR): 16.6 (+37.1% YoY | +12.2% QoQ)
Beta Drugs Limited has informed the Exchange about Schedule of meet
Intimation · 22 Oct 2026, 4:00 pm
Beta Drugs Schedules Q2 & H1 FY27 Earnings Call on 22nd Oct'26 Beta Drugs Limited will host an earnings conference call on 22nd Oct'26 at 4:00 PM IST to discuss its operational and financial performance for Q2 & H1 FY27. Organized by PhillipCapital (India) Private Limited, the call will feature senior management, including Chairman & Managing Director Rahul Batra, Chief Financial Officer Nipun Arora, and Director of Sales & Marketing Ashutosh Shukla. Dial-in details include primary Indian access lines (+91 22 6280 1143 / +91 22 7115 8044) alongside international toll-free numbers.
Beta Drugs Limited has informed the Exchange about Schedule of meet
Intimation · 22 Oct 2026, 4:00 pm
Beta Drugs Schedules Q2 & H1 FY27 Earnings Conference Call Beta Drugs Limited will host an earnings conference call on 22nd Oct'26 at 4:00 PM IST to discuss its operational and financial performance for Q2 & H1 FY27. Organised by PhillipCapital (India) Private Limited, the call will feature senior management, including Chairman & Managing Director Rahul Batra, CFO Nipun Arora, and Director of Sales & Marketing Ashutosh Shukla. Universal dial-in numbers include +91 22 6280 1143 and +91 22 7115 8044, with international toll-free options available for the US, UK, Singapore, and Hong Kong.
BETA DRUGS LIMITED has informed the Exchange about Board Meeting to be held on 22-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2026 .
Intimation · 22 Oct 2026, 5:30 am
Beta Drugs Schedules Board Meeting to Consider Q2 FY27 Financial Results Beta Drugs Limited has notified the exchange that its Board of Directors will meet on 22nd Oct'26 to consider and approve the unaudited financial results for the quarter ended Sep'26.
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 22 Oct 2026, 5:30 am
Beta Drugs Schedules Board Meeting to Approve Q2 FY27 Financial Results Beta Drugs Ltd. announced that its Board of Directors will meet on 22nd Oct'26 to consider and approve the unaudited standalone and consolidated financial results for the quarter and half-year ended 30th Sep'26. In accordance with SEBI insider trading regulations, the trading window for designated persons and their immediate relatives has been closed effective 1st Oct'26 and will remain closed until 24th Oct'26, 48 hours following the declaration of the financial results.
Beta Drugs Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 30, 2026. Further, the company has informed the Exchange regarding voting results.
Annual General Meeting · 01 Oct 2026, 9:28 pm
Beta Drugs Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 30, 2026
Annual General Meeting · 30 Sept 2026, 5:05 pm
Beta Drugs Limited has informed the Exchange about Azerbaijan Oncology Market Regulatory & Commercialisation update
Others (Uncategorized) · 22 Sept 2026, 2:30 pm
Beta Drugs Secures Key Oncology Portfolio Approvals in Azerbaijan Market Beta Drugs received regulatory approvals in Azerbaijan for its oncology portfolio across liquid injectables, lyophilised injectables, tablets, capsules, and oral suspensions. The company has filed 15 oncology dossiers, with an additional 15 products ready for filing next month. Positioned to be among the few oncology players in the country, Beta Drugs is targeting commercialisation and initial business generation during the current financial year, aligning with its broader strategy to expand its international oncology franchise across emerging global markets.
Beta Drugs Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 30, 2026
Annual General Meeting · 05 Sept 2026, 9:46 pm
Beta Drugs Limited has informed the Exchange about 'Beta Drugs Limited has informed the Exchange that Register of Members & Share Transfer Books of the Company will remain closed from 24-Sep-2026 to 30-Sep-2026 for the purpose of ANNUAL GENERAL MEETING to be held on 30.09.2026
Annual General Meeting · 03 Sept 2026, 11:39 pm
Beta Drugs Limited has informed the Exchange regarding Notice of undefined to be held on September 30, 2026
Annual General Meeting · 03 Sept 2026, 11:34 pm
Beta Drugs Limited has informed the Exchange regarding Outcome of Board Meeting held on September 03, 2026.
Outcome · 03 Sept 2026, 11:26 pm
Beta Drugs Board Approves Auditor Appointments and Director Re-appointment Beta Drugs Ltd.'s board met on 3rd Sep'26, scheduling its AGM for 30th Sep'26 with a book closure period from 24th Sep'26 to 30th Sep'26. Crucial leadership resolutions include the re-appointment of Mr. Ashutosh Shukla as Whole-Time Director for a five-year term starting 20th Jan'27, alongside revised remuneration. Additionally, the board re-appointed Khurana Sharma and Co. as Statutory Auditors for two years (FY27-FY28) and named Charu Jindal & Co. and V.K. Srivastava & Associates as Cost and Internal Auditors, respectively, for FY27.
To consider other business matters
Others (Uncategorized) · 31 Aug 2026, 5:39 pm
Beta Drugs Schedules Board Meeting for Sep'26 Beta Drugs has scheduled a Board of Directors meeting for 3rd Sep'26. The key agenda is to consider and approve the date, time, and place of the 21st Annual General Meeting (AGM). The board will also approve the draft notice for the AGM and the Director's Report for the period ended 31st Mar'26.
BETA DRUGS LIMITED has informed the Exchange about Board Meeting to be held on 03-Sep-2026 to consider Other business.
Intimation · 31 Aug 2026, 5:31 pm
Beta Drugs Schedules Board Meeting for Sep-26 Beta Drugs has announced a Board of Directors meeting scheduled for 03-Sep-26. The primary agenda cited is to consider and discuss unspecified "Other business." Further details on the specific matters to be addressed have not yet been disclosed.
Beta Drugs Limited has informed the Exchange regarding Outcome of Board Meeting held on August 18, 2026.
Outcome · 18 Aug 2026, 5:37 pm
Beta Drugs Allots Bonus Equity Shares on CCD Conversion Beta Drugs Limited's board, in its meeting on 18th Aug'26, approved the allotment of 35,383 Bonus Equity Shares with a face value of INR 10 each. This allotment is for the holders of Compulsorily Convertible Debentures (CCDs) and follows the conversion of these CCDs into equity shares. This action will lead to a minor expansion of the company's equity base. The meeting concluded at 11:56 a.m.
Monitoring Agency Report for the Quarter ended 30th June, 2026
Others (Uncategorized) · 14 Aug 2026, 5:58 pm
Beta Drugs: Q1'27 Preferential Issue Funds Utilization Update Beta Drugs raised ₹117.01 crore via a preferential issue of equity shares and CCDs. As of 30th Jun'26, the company utilized ₹23.50 crore during the quarter, bringing total utilization to ₹37.84 crore against the planned ₹117.02 crore. Key expenditures were ₹19.94 crore for capital investment/acquisitions and ₹3.56 crore for general corporate purposes. ₹79.17 crore remains unutilized, parked in fixed deposits yielding 5.50-6.60%. Brickwork Ratings confirmed no deviations from the stated objects of the issue, with all projects proceeding without delay.
Beta Drugs Limited has informed the Exchange about Investor Presentation
Investor Presentation · 28 Jul 2026, 2:54 am
Beta Drugs Reports Strong Q1-FY27 with Margin Expansion and Revenue Growth Beta Drugs reported robust Q1-FY27 results with consolidated revenue of INR 1,255 Mn, up 25.2% YoY and 33.5% QoQ. EBITDA grew 39.1% YoY to INR 274 Mn, with margins expanding 217 bps YoY to 21.83%. PAT increased 41.0% YoY to INR 165 Mn, yielding a PAT margin of 13.15%. Key growth drivers were the Branded Oncology (47% YoY) and CMO (41% YoY) segments. Gross margin improved to 56.6% due to a favourable product mix. The company reiterated its FY27 revenue growth guidance of 20-25%.
The Exchange had sought clarification from Beta Drugs Limited for the quarter ended 30-Jun-2026 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: The response of the Company is enclosed.
Others (Uncategorized) · 23 Jul 2026, 11:24 pm
Beta Drugs Q1FY27 Net Profit Rises 35% YoY Beta Drugs reported a consolidated net profit of ₹15.80 cr for Q1FY27, a 35% YoY increase from ₹11.70 cr in Q1FY26. Revenue from operations grew 25% YoY to ₹125.55 cr. Sequentially, net profit surged 75% from ₹9.05 cr while revenue increased 34%. Consolidated basic EPS for the quarter was ₹14.78, up from ₹11.59 YoY. The company submitted revised audit reports on 23rd Jul'26 to include the UDIN, correcting an earlier oversight in their 20th Jul'26 filing.
The Exchange has sought clarification from Beta Drugs Limited for the quarter ended 30-Jun-2026 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: The response of the Company is awaited.
Others (Uncategorized) · 22 Jul 2026, 11:47 pm
Beta Drugs: Exchange Seeks Clarification on Q1FY27 Financials The Exchange has sought clarification from Beta Drugs Limited regarding its financial results for the quarter ended 30 Jun'26, under Regulation 33 of SEBI's LODR. The company's response is currently awaited.
Beta Drugs Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32
Others (Uncategorized) · 20 Jul 2026, 8:38 pm
Beta Drugs Reports No Deviation in Use of Preferential Issue Proceeds Beta Drugs confirmed no deviation in utilizing the Rs 117.01 crores raised via a preferential issue on 25 Nov'24. For the quarter ending 30 Jun'26, the company reported total fund utilization of Rs 47.87 crores. Key expenditures include Rs 19.95 crores for capital investments, Rs 13.85 crores for general corporate purposes, and Rs 9.52 crores for a new manufacturing setup. The Audit Committee reviewed the utilization with no adverse comments. All proceeds were used in line with the stated objectives.
Beta Drugs Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
Financial Result · 20 Jul 2026, 2:30 pm
Beta Drugs Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR) ■ Revenue: 1,25,54,95,638 (+25.3% YoY | +33.6% QoQ) ■ EBITDA: 27,36,74,499 (+38.9% YoY | +54.8% QoQ) ■ EBITDA Margin (%): 21.8 (+213 bps YoY | +298 bps QoQ) ■ PAT: 15,80,18,248 (+35.1% YoY | +74.6% QoQ) ■ EPS (INR): 14.8 (+27.5% YoY | +65.5% QoQ)